Skip to main content

Table 1 Characteristics of included studies

From: The effects of coenzyme Q10 supplementation on lipid profiles among patients with coronary artery disease: a systematic review and meta-analysis of randomized controlled trials

Authors (Ref)

Publication year

Sample size (control/intervention)

Country/population

Intervention (name and daily dose)

Duration

Age (control, intervention)

Presented data

Belardinelli et al. [23]

2006

21/21

Italy/chronic HF

CoQ10 100 mg/day

4 weeks

60 ± 8

TC, LDL-C, TG, HDL-C

Dai Y et al. [24]

2011

28/28

Hong Kong/left ventricular systolic dysfunction

CoQ10 300 mg/ day

8 weeks

65.9 ± 12.5, 59.9 ± 13.1

TC, LDL-C, HDL-C, Lp(a)

Mohseni et al. [15]

2015

26/26

Iran/acute myocardial infarction

CoQ10 200 mg/day

12 weeks

48.4 ± 0.5, 47.6 ± 0.3

TC, LDL-C, TG, HDL-C

Mirhashemi et al. [25]

2016

30/30

Iran/T2DM with CAD

CoQ10 100 mg/day

8 weeks

68.9 ± 9.6

Lp(a)

Pourmoghaddas M et al. [26]

2013

30/32

Iran/statin treated coronary heart failure patients

CoQ10 200 mg/ day

16 weeks

48.0 ± 8.6, 47.6 ± 8.2

TC, LDL-C

Singh et al. [19]

1999

22/25

India/CAD

CoQ10 120 mg/day

4 weeks

50.70 ± 12.5, 54.47 ± 14.6

TC, LDL-C, HDL-C, Lp(a)

Singh et al. [14]

2003

71/73

India/myocardial infarction

CoQ10 120 mg/day

48 weeks

51 ± 9,

51 ± 10

TC, LDL-C, TG, HDL-C

Sharifi et al. [13]

2017

31/32

Iran/myocardial infarction

CoQ10 150 mg/day and L-carnitine 1200 mg/day

3 months

59 ± 9

TC

  1. CAD coronary artery disease, HDL-C high density lipoprotein-cholesterol, HF heart failure, LDL-C low density lipoprotein-cholesterol, Lp(a) Lipoprotein(a), TC total cholesterol, TG triglycerides, T2DM type 2 diabetes mellitus